Lisata Therapeutics, Inc.

09/02/2025

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-present-hc-wainwright-27th-annual-global

08/28/2025

How does certepetide work?

Our lead investigational product targets alpha-v integrins primarily on tumor cells and vasculature. When bound, it creates a CendR fragment that activates a novel uptake pathway, allowing anti-cancer drugs to pe*****te solid tumors more effectively while sparing healthy tissue. Certepetide also modifies the tumor microenvironment, enhancing immunotherapy effectiveness and inhibiting metastasis.

Watch our short film to learn more: https://www.youtube.com/watch?v=dd-SgaBoWac

08/22/2025

Lisata Therapeutics' certepetide pipeline targets advanced solid tumors across multiple indications through our CendR Platform® technology, which enables enhanced tumor-targeted delivery of anti-cancer agents.

Current clinical programs include:
🔬ASCEND trial in metastatic pancreatic cancer
🔬BOLSTER trial in cholangiocarcinoma
🔬 iLSTA trial in locally advanced, nonresectable PDAC
🔬CENDIFOX trial in pancreatic, colon, and appendiceal cancers
🔬Glioblastoma trial

Certepetide has received Fast Track designation and multiple Orphan Drug Designations from the FDA, recognizing significant unmet medical needs in these patient populations.

For more info on our ongoing clinical programs, visit: https://www.lisata.com/active-clinical-trials/

08/19/2025

Cholangiocarcinoma (bile duct cancer) represents a significant area of unmet medical need in oncology. This rare cancer poses unique treatment challenges for patients and healthcare providers.

At Lisata Therapeutics, our BOLSTER Phase 2a trial is evaluating certepetide in combination with standard-of-care therapy for first-line cholangiocarcinoma. Certepetide has received Orphan Drug Designation from the U.S. FDA for this indication.

Learn more about cholangiocarcinoma: https://www.lisata.com/patients-families/cholangiocarcinoma-bile-duct-cancer-symptoms/

This information is for educational purposes only. Always consult healthcare providers for medical advice.

08/15/2025

In case you missed it, Lisata Therapeutics announced an expanded relationship with GATC Health to advance AI-driven drug discovery and development.

This strategic alliance combines Lisata's proven drug development expertise with GATC's AI-powered Multiomics Advanced Technology™ (MAT) platform to accelerate development of an AI-discovered non-opioid therapeutic for opioid use disorder, with Phase 1 human trials targeted for early 2026.

CEO David J. Mazzo, Ph.D. emphasized the symbiotic relationship between the organizations, noting how AI technologies could create substantial value for the pharmaceutical industry while shortening drug discovery timelines from years to months.

Watch: https://www.youtube.com/watch?v=AQlxboXcBXw
For more: https://bit.ly/3IHQoZR

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo and GATC Health chief business officer Tyrone Lam talked with Proactive's Stephen Gunnion about the ...

08/11/2025

In case you missed it, Lisata Therapeutics announced that the U.S. Patent and Trademark Office issued a new composition of matter patent for certepetide, extending intellectual property protection through March 2040 with potential for patent term extension.

This patent covers certepetide's chemical structure, manufacturing methods, and cancer treatment applications—representing the strongest form of intellectual property protection available.

CEO David J. Mazzo, Ph.D. noted this milestone significantly boosts Company value by delaying generic encroachment for approximately two decades while strengthening negotiating positions with potential partners.

Read more: https://www.proactiveinvestors.com/companies/news/1074770/lisata-therapeutics-expands-ip-with-key-patent-covering-certepetide-s-chemical-structure-and-uses-1074770.html

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate...

08/07/2025

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update.

Read full release: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-second-quarter-2025-financial/

08/07/2025

Join us today for our Second Quarter 2025 Financial Results and Business Update Conference Call at 4:30 p.m. ET.

To participate on the call, please register here: https://register-conf.media-server.com/register/BI554649d050f44a2a81a3ec7f4abc26d5

Tune in to the webcast here: https://edge.media-server.com/mmc/p/5ranib5w/

07/31/2025

On Thursday, August 7, we will announce our Second Quarter 2025 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET.

To participate on the call, please register here: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-report-second-quarter-2025-financial-results

07/22/2025

Our President and CEO David J. Mazzo, Ph.D. and Chief Medical Officer Kristen K. Buck, MD, recently participated in the latest episode of the WTR Healthcare Spotlight podcast.

The conversation focused on certepetide, Lisata’s novel tumor-penetrating therapy, and encouraging preliminary Phase 2b results in metastatic pancreatic cancer. Key discussion topics included insights on our lead program, key partnerships, and what’s next for Lisata Therapeutics.

Listen now on:
🎧Apple: https://podcasts.apple.com/us/podcast/lisata-therapeutics-ceo-dr-david-mazzo-and-cmo-dr/id1795488592?i=1000717947908

🎧Spotify: https://open.spotify.com/episode/1tMC216pC6ygK6rN3xu0r0

🎧Website: https://www.watertowerresearch.com/media-detail/2231/Media

🎧All platforms: https://pod.link/1693448305

WTR Small-Cap Spotlight is your weekly guide to uncovering hidden value in the world of small-cap stocks. Each episode features insightful interviews with C-level executives, industry thought leaders, and Water Tower’s expert analysts. Tune in for actionable investment ideas and in-depth discussio...

07/17/2025

Today, on Glioblastoma Awareness Day, we honor the incredible strength of patients, survivors, and caregivers affected by glioblastoma and other brain cancers.

Glioblastoma is one of the most complex, treatment-resistant, and deadliest types of brain cancer. At Lisata Therapeutics, Inc., we're deeply committed to advancing new treatment options. Our investigational drug, certepetide, holds Orphan Drug Designation for malignant glioma in the U.S., and we're actively exploring its potential to significantly enhance drug pe*******on in advanced solid tumors, including glioblastoma multiforme.

We proudly stand with the brain tumor community, united in the pursuit of better treatments and outcomes.

07/17/2025

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Read the press release for details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-and-warpnine-announce-ilsta-trial-enrollment